<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04885647</url>
  </required_header>
  <id_info>
    <org_study_id>TB1901EPO</org_study_id>
    <nct_id>NCT04885647</nct_id>
  </id_info>
  <brief_title>A Study of YPEG-rhEPO in Patients Suffered From Anemia Due to Chronic Kidney Disease</brief_title>
  <official_title>A Multicenter, Randomized, Open-label, Phase 2 Study of YPEG-rhEPO in Patients Suffered From Anemia Due to Chronic Kidney Disease, Who Has Previously Treated With rhEPO and the Hemoglobin Maintenance in a Stabilize State</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Xiamen Amoytop Biotech Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>First Affiliated Hospital of Zhejiang University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Xiamen Amoytop Biotech Co., Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the effectiveness and safety of YPEG rhEPO, a&#xD;
      recombinant human erythropoietin pegylated by Y shape polyethylene glycol, in patients with&#xD;
      anemia due to Chronic Kidney Disease (CKD) as assessed by hemoglobin maintenance, adverse&#xD;
      events and health-related quality of life.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 12, 2020</start_date>
  <completion_date type="Anticipated">June 2022</completion_date>
  <primary_completion_date type="Anticipated">June 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Changes of mean hemoglobin compared to baseline.</measure>
    <time_frame>14 weeks for every two weeks groups, and 16 weeks for every four weeks groups.</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients with hemoglobin keeping within the target range (the target hemoglobin range is defined as hemoglobin keeping between 100g/L and 120g/L).</measure>
    <time_frame>14 weeks for every two weeks groups, and 16 weeks for every four weeks groups.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients with hemoglobin fluctuations within ±10g/L compared to baseline.</measure>
    <time_frame>14 weeks for every two weeks groups, and 16 weeks for every four weeks groups.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean time of hemoglobin keeping within the target range.</measure>
    <time_frame>14 weeks for every two weeks groups, and 16 weeks for every four weeks groups.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean time from baseline to the first dose adjustment.</measure>
    <time_frame>14 weeks for every two weeks groups, and 16 weeks for every four weeks groups.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes of hemoglobin compared to baseline at the time of first dose adjustment.</measure>
    <time_frame>14 weeks for every two weeks groups, and 16 weeks for every four weeks groups.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients with dose adjustment.</measure>
    <time_frame>14 weeks for every two weeks groups, and 16 weeks for every four weeks groups.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients requiring blood transfusion.</measure>
    <time_frame>14 weeks for every two weeks groups, and 16 weeks for every four weeks groups.</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Renal Anemia of Chronic Kidney Disease</condition>
  <arm_group>
    <arm_group_label>Arm1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Low dose once every 2 weeks group</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Low dose once every 4 weeks group</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>High dose once every 2 weeks group</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>High dose once every 4 weeks group</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>YPEG-rhEPO</intervention_name>
    <description>YPEG-rhEPO，low dose，were subcutaneous injected once every two weeks for 13 weeks.</description>
    <arm_group_label>Arm1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>YPEG-rhEPO</intervention_name>
    <description>YPEG-rhEPO，low dose，were subcutaneous injected once every four weeks for 13 weeks.</description>
    <arm_group_label>Arm2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>YPEG-rhEPO</intervention_name>
    <description>YPEG-rhEPO, high dose，were subcutaneous injected once every two weeks for 13 weeks.</description>
    <arm_group_label>Arm3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>YPEG-rhEPO</intervention_name>
    <description>YPEG-rhEPO，high dose，were subcutaneous injected once every four weeks for 13 weeks.</description>
    <arm_group_label>Arm4</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Aged between 18 and 70 years old, including 18 and 70 years.&#xD;
&#xD;
          -  Subjects who are diagnosed of chronic kidney disease and receiving hemodialysis (KT/V&#xD;
             greater than or equal to 1.2). And those who had received hemodialysis, performed 2 to&#xD;
             3 times a week and 4 to 5 hours for every dialysis, for at least 12 weeks prior to&#xD;
             deliver of YPEG-EPO.&#xD;
&#xD;
          -  Subjects receiving rhEPO treatment, including subcutaneous and intravenous injection,&#xD;
             for anemia due to chronic kidney disease for at least 12 weeks before randomized. And&#xD;
             in addition, the serum hemoglobin should keep stable during the previous 12 weeks,&#xD;
             which was defined as serum hemoglobin obtained from tests taken once a month (once a&#xD;
             month means at least 4 weeks interval between two tests) were always kept between&#xD;
             100g/L and 120g/L, or else mean hemoglobin of two different tests, which were taken at&#xD;
             least 4 weeks apart, is between 100g/L and 120g/L.&#xD;
&#xD;
          -  Transferrin saturation (TSAT) greater than 20% or serum ferritin (SF) greater than&#xD;
             200ng/mL, serum folate greater or equal to the lower normal limit (ULN), serum vitamin&#xD;
             B12 greater or equal to ULN，before enrollment.&#xD;
&#xD;
          -  Understand and sign the informed consent form voluntarily.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Women of pregnancy, lactating, or planning to pregnant, or patients who are planning&#xD;
             to donate sperms/eggs during the study period.&#xD;
&#xD;
          -  Subjects who are allergic to rhEPO or any of its components, or with any other&#xD;
             evidenced allergy history that make it not suitable for participation.&#xD;
&#xD;
          -  Subjects who are receiving Roxadustat Capsules at screening.&#xD;
&#xD;
          -  Anemia caused by diseases or causes other than CKD, such as bleeding, hemolysis,&#xD;
             vitamin or folate deficiency. Obvious bleeding evidence that requires blood&#xD;
             transfusion during the lead-in period.&#xD;
&#xD;
          -  Subjects suffering from pure red-cell anemia (PRCA) according to previously&#xD;
             erythropoietin treatment.&#xD;
&#xD;
          -  Subjects with serious disease or function deficiency in major organ/system, such as：&#xD;
&#xD;
               1. Medical history of myocardial infarction, cerebral stroke, vascular access&#xD;
                  thrombosis, or pulmonary embolism. Combined congestive heart failure (NYHA&#xD;
                  cardiac function equal to or grade than III). Hypertensions poorly controlled by&#xD;
                  medication (systolic blood pressure higher than 170mmHg and/or diastolic blood&#xD;
                  pressure higher than 100mmHg), or postural hypotension (systolic blood pressure&#xD;
                  below 90mmHg).&#xD;
&#xD;
               2. Medical history of malignancy, hematological disease, obvious bleeding disease,&#xD;
                  epilepsy, neuropsychiatric disease, or family history of neuropsychiatric&#xD;
                  disease.&#xD;
&#xD;
               3. Poorly controlled autoimmune diseases (including but not limit to systemic lupus&#xD;
                  erythematosus, rheumatoid arthritis, multiple sclerosis, autoimmune&#xD;
                  thrombocytopenia).&#xD;
&#xD;
               4. Poorly controlled endocrine diseases, (including but not limit to thyroid&#xD;
                  disease, parathyroid disease, diabetes mellitus).&#xD;
&#xD;
               5. Co-infected with HAV, HBV, HCV, HIV, Syphilis, etc..&#xD;
&#xD;
               6. Currently suffering from severe infection or inflammation (C-reactive protein&#xD;
                  greater than 30mg / L), or currently receiving antibiotics.&#xD;
&#xD;
          -  Red blood cell count greater than 6.0×10^12/L for men while greater than 5.5×10^12/L&#xD;
             for female; Platelets greater than 500×10^9/L; serum albumin lower than 30g/L; Alanine&#xD;
             aminotransferase higher than 2 ULN, aspartame aminotransferase higher than 2ULN;&#xD;
             Parathyroid hormone greater than 800pg/mL.&#xD;
&#xD;
          -  Subjects who plan to undergo coronary artery bypass grafting (CABG), to undergo&#xD;
             orthopedic surgery, to receive kidney transplantation, or to undergo any other major&#xD;
             operation during the study period.&#xD;
&#xD;
          -  Drug addicts or alcoholics.&#xD;
&#xD;
          -  Vascular malformations (such as internal jugular vein malformation) makes it&#xD;
             inappropriately for Hemodialysis catheterization.&#xD;
&#xD;
          -  Expected survival of a certain subject is less than 12 months.&#xD;
&#xD;
          -  Subjects participated in any other clinical trial within 3 months prior to screening.&#xD;
&#xD;
          -  Any other situation that is not suitable for participation in this study according to&#xD;
             the investigator's judgment.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Xiaoyan Yi, MD</last_name>
    <phone>+86 592 6889121</phone>
    <email>yixiaoyan@amoytop.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Beijing Anzhen Hospital,Capital Medical University</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xiaoyan Yi, MD</last_name>
      <phone>+86 592 6889121</phone>
      <email>yixiaoyan@amoytop.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>The Second Affiliated Hospital Of Chongqing Medical University</name>
      <address>
        <city>Chongqing</city>
        <state>Chongqing</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xiaoyan Yi, MD</last_name>
      <phone>+86 592 6889121</phone>
      <email>yixiaoyan@amoytop.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>The First Affiliated Hospital Of Guangzhou Medical University</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xiaoyan Yi, MD</last_name>
      <phone>+86 592 6889121</phone>
      <email>yixiaoyan@amoytop.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>The First Affiliated Hospital of Jinan University</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xiaoyan Yi, MD</last_name>
      <phone>+86 592 6889121</phone>
      <email>yixiaoyan@amoytop.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>The Third Affiliated Hospital of Sun Yat sen University</name>
      <address>
        <city>Guanzhou</city>
        <state>Guangdong</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xiaoyan Yi, MD</last_name>
      <phone>+86 592 6889121</phone>
      <email>yixiaoyan@amoytop.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Renmin Hospital of Wuhan University/Hubei General Hospital</name>
      <address>
        <city>Wuhan</city>
        <state>Hubei</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xiaoyan Yi, MD</last_name>
      <phone>+86 592 6889121</phone>
      <email>yixiaoyan@amoytop.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>The Third Xiangya Hospital Of Central South University</name>
      <address>
        <city>Changsha</city>
        <state>Hunan</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xiaoyan Yi, MD</last_name>
      <phone>+86 592 6889121</phone>
      <email>yixiaoyan@amoytop.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Xiangya Hospital Central South University</name>
      <address>
        <city>Changsha</city>
        <state>Hunan</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xiaoyan Yi, MD</last_name>
      <phone>+86 592 6889121</phone>
      <email>yixiaoyan@amoytop.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>The First Affiliated Hospital Of Baotou Medical college,Inner Mongolia University Of Science and Technology</name>
      <address>
        <city>Hohhot</city>
        <state>Inner Mongol</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xiaoyan Yi, MD</last_name>
      <phone>+86 592 6889121</phone>
      <email>yixiaoyan@amoytop.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Huai'an Second People's Hospital/The Affiliated Huaian Hospital Of Xuzhou Medical University</name>
      <address>
        <city>Huai'an</city>
        <state>Jiangsu</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xiaoyan Yi, MD</last_name>
      <phone>+86 592 6889121</phone>
      <email>yixiaoyan@amoytop.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Affiliated Zhongshan Hospital of Dalian University</name>
      <address>
        <city>Dalian</city>
        <state>Liaoning</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xiaoyan Yi, MD</last_name>
      <phone>+86 592 6889121</phone>
      <email>yixiaoyan@amoytop.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Xi'an Gaoxin Hospital</name>
      <address>
        <city>Xi'an</city>
        <state>Shanxi</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xiaoyan Yi, MD</last_name>
      <phone>+86 592 6889121</phone>
      <email>yixiaoyan@amoytop.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>The First Affiliated Hospital Of Chengdu Medical college</name>
      <address>
        <city>Chengdu</city>
        <state>Sichuan</state>
        <zip>361028</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xiaoyan Yi, MD</last_name>
      <phone>+86 592 6889121</phone>
      <email>yixiaoyan@amoytop.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Tianjin First Central Hospital</name>
      <address>
        <city>Tianjin</city>
        <state>Tianjin</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xiaoyan Yi, MD</last_name>
      <phone>+86 592 6889121</phone>
      <email>yixiaoyan@amoytop.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Tianjin People's Hospital</name>
      <address>
        <city>Tianjin</city>
        <state>Tianjin</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xiaoyan Yi, MD</last_name>
      <phone>+86 592 6889121</phone>
      <email>yixiaoyan@amoytop.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>The First Affiliated Hospital, College of Medicine, Zhejiang University</name>
      <address>
        <city>Hangzhou</city>
        <state>Zhejiang</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xiaoyan Yi, MD</last_name>
      <phone>+86 592 6889121</phone>
      <email>yixiaoyan@amoytop.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Lishui Municipal Central Hospital</name>
      <address>
        <city>Lishui</city>
        <state>Zhejiang</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xiaoyan Yi, MD</last_name>
      <phone>+86 592 6889121</phone>
      <email>yixiaoyan@amoytop.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>May 8, 2021</study_first_submitted>
  <study_first_submitted_qc>May 12, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">May 13, 2021</study_first_posted>
  <last_update_submitted>May 12, 2021</last_update_submitted>
  <last_update_submitted_qc>May 12, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 17, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>YPEG rhEPO</keyword>
  <keyword>rhEPO</keyword>
  <keyword>erythropoietin</keyword>
  <keyword>anemia</keyword>
  <keyword>dialysis</keyword>
  <keyword>hemodialysis</keyword>
  <keyword>chronic kidney disease</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Renal Insufficiency, Chronic</mesh_term>
    <mesh_term>Anemia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

